T
Travis K. Warren
Researcher at United States Army Medical Research Institute of Infectious Diseases
Publications - 68
Citations - 5640
Travis K. Warren is an academic researcher from United States Army Medical Research Institute of Infectious Diseases. The author has contributed to research in topics: Ebola virus & Virus. The author has an hindex of 33, co-authored 65 publications receiving 4698 citations. Previous affiliations of Travis K. Warren include SIGA Technologies & Washington State University.
Papers
More filters
Journal ArticleDOI
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren,Robert Jordan,Michael K. Lo,Adrian S. Ray,Richard L. Mackman,Veronica Soloveva,Dustin Siegel,Michel Perron,Roy Bannister,Hui Hon Chung,Nate Larson,Robert G. Strickley,Jay Wells,Kelly S. Stuthman,Sean A. Van Tongeren,Nicole L. Garza,Ginger Donnelly,Amy C. Shurtleff,Cary Retterer,Dima N. Gharaibeh,Rouzbeh Zamani,Tara Kenny,Brett P. Eaton,Elizabeth C. Grimes,Lisa S. Welch,Laura Gomba,Catherine L. Wilhelmsen,Donald K. Nichols,Jonathan E. Nuss,Elyse R. Nagle,Jeffrey R. Kugelman,Gustavo Palacios,Edward Doerffler,Sean Neville,Ernest Carra,Michael O. Clarke,Lijun Zhang,Willard Lew,Bruce Ross,Queenie Wang,Kwon Soo Chun,Lydia Wolfe,Darius Babusis,Yeojin Park,Kirsten M. Stray,Iva Trancheva,Joy Y. Feng,Ona Barauskas,Yili Xu,Pamela Wong,Molly R. Braun,Mike Flint,Laura K. McMullan,Shan Shan Chen,Rachel Fearns,S. Swaminathan,Douglas L. Mayers,Christina F. Spiropoulou,William A. Lee,Stuart T. Nichol,Tomas Cihlar,Sina Bavari +61 more
TL;DR: These results show the first substantive post-exposure protection by a small-molecule antiviral compound against EBOV in nonhuman primates, and the broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenavirus, and coronavirus suggests the potential for wider medical use.
Journal ArticleDOI
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
Dustin Siegel,Hui Hon Chung,Edward Doerffler,Michael O'neil Hanrahan Clarke,Kwon Soo Chun,Lijun Zhang,Sean Neville,Ernest Carra,Willard Lew,Bruce Ross,Queenie Wang,Lydia Wolfe,Robert Jordan,Veronica Soloveva,John E. Knox,Jason K. Perry,Michel Perron,Kirsten M. Stray,Ona Barauskas,Joy Y. Feng,Yili Xu,Gary Lee,Arnold L. Rheingold,Adrian S. Ray,Roy Bannister,Robert G. Strickley,S. Swaminathan,William A. Lee,Sina Bavari,Tomas Cihlar,Michael K. Lo,Travis K. Warren,Richard L. Mackman +32 more
TL;DR: A robust diastereoselective synthesis provided sufficient quantities of 4b to enable preclinical efficacy in a non-human-primate EBOV challenge model and structure activity relationships established that the 1′-CN group and C-linked nucleobase were critical for optimal anti-EBOV potency and selectivity against host polymerases.
Journal ArticleDOI
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Travis K. Warren,Jay Wells,Rekha G. Panchal,Kelly S. Stuthman,Nicole L. Garza,Sean A. Van Tongeren,Lian Dong,Cary Retterer,Brett P. Eaton,Gianluca Pegoraro,Shelley P. Honnold,Shanta Bantia,Pravin L. Kotian,Xilin Chen,Brian R. Taubenheim,Lisa S. Welch,Dena M. Minning,Y.S. Babu,William P. Sheridan,Sina Bavari +19 more
TL;DR: It is shown that BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells, and exhibits broad-spectrum antiviral activity against numerous viruses.
Journal ArticleDOI
A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
Peter B. Madrid,Sidharth Chopra,Ian D. Manger,Lynne Gilfillan,Tiffany R. Keepers,Amy C. Shurtleff,Carol E. Green,Lalitha V. Iyer,Holli Hutcheson Dilks,Robert A. Davey,Andrey A. Kolokoltsov,Ricardo Carrion,Jean L. Patterson,Sina Bavari,Rekha G. Panchal,Travis K. Warren,Jay Wells,Walter H. Moos,RaeLyn L. Burke,Mary J. Tanga +19 more
TL;DR: The feasibility of repurposing existing drugs to face novel threats is demonstrated and this represents the first effort to apply this approach to high containment bacteria and viruses.
Journal ArticleDOI
Evaluation of Ebola Virus Inhibitors for Drug Repurposing.
Peter B. Madrid,Rekha G. Panchal,Travis K. Warren,Amy C. Shurtleff,Aaron N. Endsley,Carol E. Green,Andrey A. Kolokoltsov,Robert A. Davey,Ian D. Manger,Lynne Gilfillan,Sina Bavari,Mary J. Tanga +11 more
TL;DR: The results show the benefits and specific challenges associated with drug repurposing and highlight the need for careful evaluation of approved drugs as rapidly deployable countermeasures against future pandemics.